JP2018503373A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503373A5
JP2018503373A5 JP2017534648A JP2017534648A JP2018503373A5 JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5 JP 2017534648 A JP2017534648 A JP 2017534648A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5
Authority
JP
Japan
Prior art keywords
expression level
determined
cancer
correlates
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067878 external-priority patent/WO2016109546A2/en
Publication of JP2018503373A publication Critical patent/JP2018503373A/ja
Publication of JP2018503373A5 publication Critical patent/JP2018503373A5/ja
Priority to JP2021031306A priority Critical patent/JP7325463B2/ja
Pending legal-status Critical Current

Links

JP2017534648A 2014-12-30 2015-12-29 がんの予後診断及び治療のための方法及び組成物 Pending JP2018503373A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021031306A JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098055P 2014-12-30 2014-12-30
US62/098,055 2014-12-30
PCT/US2015/067878 WO2016109546A2 (en) 2014-12-30 2015-12-29 Methods and compositions for prognosis and treatment of cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021031306A Division JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2018503373A JP2018503373A (ja) 2018-02-08
JP2018503373A5 true JP2018503373A5 (enExample) 2019-01-31

Family

ID=55315702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534648A Pending JP2018503373A (ja) 2014-12-30 2015-12-29 がんの予後診断及び治療のための方法及び組成物
JP2021031306A Active JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021031306A Active JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Country Status (5)

Country Link
US (2) US11236394B2 (enExample)
EP (1) EP3240908A2 (enExample)
JP (2) JP2018503373A (enExample)
CN (1) CN107208138A (enExample)
WO (1) WO2016109546A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US20190376146A1 (en) * 2016-11-24 2019-12-12 Daiichi Sankyo Company, Limited Method for predicting sensitivity of cancer to treatment with pd-1 immune checkpoint inhibitor
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
EP3333268A1 (en) * 2016-12-09 2018-06-13 Institut Paoli Calmettes Biomarker panel for prognosis of bladder cancer
WO2018122249A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
JP7206203B2 (ja) * 2017-02-07 2023-01-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル がんの重症度を評価するためのｔｉｍ－３
CN106950371B (zh) * 2017-02-17 2019-03-08 张灏 Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
CN111033631B (zh) 2017-06-13 2024-03-12 波士顿基因公司 用于生成分子功能谱、对其进行可视化和分类的系统和方法
EP3638695A4 (en) * 2017-06-14 2021-06-30 Icahn School of Medicine at Mount Sinai METHOD OF DETECTION AND TREATMENT OF IMMUNOTHERAPY-RESPONDING CLASSES OF HEPATOCELLULAR CARCINOMA
KR102348291B1 (ko) * 2017-06-14 2022-01-07 연세대학교 산학협력단 암 환자의 치료 반응성을 예측하는 방법
AU2018301704A1 (en) * 2017-07-14 2020-03-05 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
WO2019117132A1 (ja) * 2017-12-12 2019-06-20 地方独立行政法人神奈川県立病院機構 がん免疫療法の予後予測のためのバイオマーカー
US20210363590A1 (en) * 2018-05-21 2021-11-25 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
CN108823309B (zh) * 2018-06-11 2021-11-30 北京大学人民医院 检测kiaa0125基因表达水平的物质在辅助鉴定急性淋巴细胞白血病中的应用
GB201810190D0 (en) * 2018-06-21 2018-08-08 Cancer Research Tech Ltd Prognostic and treatment response predictive method
WO2020033715A1 (en) * 2018-08-08 2020-02-13 Cedars-Sinai Medical Center Compositions and methods for treating cancer and autoimmune diseases
KR102084196B1 (ko) * 2018-08-29 2020-03-03 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
ES3068417T3 (en) * 2018-09-13 2026-05-29 Nkarta Inc Natural killer cell compositions and immunotherapy methods for treating a liver tumor
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
MX2021006578A (es) * 2018-12-05 2021-07-07 Genentech Inc Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
CN109880894A (zh) * 2019-03-05 2019-06-14 杭州西合森医学检验实验室有限公司 基于RNAseq的肿瘤免疫微环境预测模型的构建方法
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2020201362A2 (en) * 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3953712A1 (en) * 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
US20220363760A1 (en) * 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
US20220241263A1 (en) * 2019-06-01 2022-08-04 Ares Trading S.A. Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes
KR102042710B1 (ko) * 2019-07-02 2019-11-08 의료법인 성광의료재단 면역체크 포인트와 관련된, 난소암 진단용 바이오마커
CN110804642B (zh) * 2019-09-10 2022-06-21 清华大学 Gpr174免疫学功能及其用途
WO2021107452A1 (ko) * 2019-11-29 2021-06-03 의료법인 성광의료재단 면역 세포 치료제에 대한 치료 반응성 예측용 바이오마커
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CN111500733B (zh) * 2020-05-27 2022-03-08 中国人民解放军军事科学院军事医学研究院 外周血单核细胞中用于非小细胞肺癌早期诊断的分子标记物
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
KR102647295B1 (ko) * 2020-09-03 2024-03-14 한국과학기술연구원 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도
WO2022053065A1 (zh) * 2020-09-14 2022-03-17 信达生物制药(苏州)有限公司 用于预测或评估肺癌患者的生物标志物、检测方法及应用
EP4247980A4 (en) * 2020-11-19 2024-10-02 Tempus AI, Inc. DETERMINATION OF CYTOTOXIC GENE SIGNATURE AND ASSOCIATED SYSTEMS AND METHODS FOR PREDICTING RESPONSE AND TREATMENT
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
EP4026918A1 (en) * 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
CN112831562A (zh) * 2021-01-25 2021-05-25 浙江科技学院 一种用于预测肝癌患者切除术后复发风险的生物标志物组合、试剂盒
US20240344138A1 (en) * 2021-03-25 2024-10-17 Feng Biosciences, Inc Targeted therapies in cancer
WO2022211620A1 (en) * 2021-04-01 2022-10-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Cd4/il-2 biomarker.
US20240336975A1 (en) 2021-07-15 2024-10-10 Vib Vzw Biomarkers Predicting Response of Breast Cancer to Immunotherapy
JP7480754B2 (ja) 2021-07-19 2024-05-10 トヨタ自動車株式会社 蓄電装置
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
US20260049359A1 (en) * 2022-05-19 2026-02-19 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
KR20240051492A (ko) * 2022-10-13 2024-04-22 주식회사 네오셀라 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법
KR20250163916A (ko) 2023-03-06 2025-11-21 제넨테크, 인크. 비소세포 폐암의 예후 및 치료 방법
JPWO2024225488A1 (enExample) * 2023-04-27 2024-10-31
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
EP2464661B1 (en) * 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
US20130023432A1 (en) * 2009-10-02 2013-01-24 Kurume University Method for predicting therapeutic effect of immunotherapy on cancer patient and/or prognosis after immunotherapy, and gene set and kit to be used therin
WO2011094483A2 (en) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US20120258878A1 (en) * 2010-08-04 2012-10-11 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
BR112014002353B1 (pt) * 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
EP2615181A1 (en) * 2012-01-10 2013-07-17 Universite Joseph Fourier - Grenoble 1 Cyclon expression for the identification and control of cancer cells
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
LT2880180T (lt) * 2012-08-06 2019-01-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai
EP2920325A2 (en) * 2012-11-15 2015-09-23 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent

Similar Documents

Publication Publication Date Title
Gavrielatou et al. Biomarkers for immunotherapy response in head and neck cancer
Galon et al. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
JP7430136B2 (ja) 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物
RU2017119231A (ru) Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
JP6815992B2 (ja) キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
JP2017536842A5 (enExample)
Badoual et al. PD-1–expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
Grenga et al. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis
JP2021521137A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
EP4104187A1 (en) Method of predicting response to chimeric antigen receptor therapy
CN112703012A (zh) 治疗癌症的方法
JP2023508947A (ja) 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム
WO2019036724A2 (en) CELLULAR THERAPIES TARGETING MOLECULAR MEDIATORS ASSOCIATED WITH DISEASE, FIBROUS, INFLAMMATORY, AND AUTOIMMUNE CONDITIONS
CN112805378A (zh) 用于评估整合核酸的方法
CN115427069A (zh) 减小遗传抽样中的统计偏差
CN113710274A (zh) 用于预测癌症免疫疗法中的长期存活的方法及组合物
WO2019224385A2 (en) Combined bispecific antibody and immuno-oncology therapies
Watson et al. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Wang et al. Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies
KR101968452B1 (ko) 면역요법 효능의 임상적 상관물
Guo et al. Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response
Sivakumar et al. Single-cell immune multi-omics and repertoire analyses in pancreatic ductal adenocarcinoma reveal differential immunosuppressive mechanisms within different tumour microenvironments
WO2023081894A2 (en) Pre-effector car-t cell gene signatures
Le et al. TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas
Mestrallet Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade